NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

Markets will not give $3B valuation to NWBO with UK approvals alone given the history of this management. We don't know how reimbursements will be structured. UK is about 5% of the global pharma market.

The fact remains they would have taken almost 4 years from the data lock to secure UK approvals. Plus the market does not trust this management to scale quickly either.

However, one thing that is extremely likely is we will be at 1.5B outstanding shares by the time we receive UK approval. Therefore, we could be potentially trading lower than where we are currently if the approvals and reimbursements drag on for another year. Perhaps a pump and dump cycle in between, but ultimately it continues to trade well under a dollar.

Outside a big pharma $300-500M upfront cash investment, nothing will change meaningfully in terms of share price.